A sign is posted in front of the Gilead Sciences headquarters on April 29, 2020 in Foster City, California.
JOHANNESBURG - Gilead Sciences is questioning a World Health Organization study rejecting its drug, Remdesivir, as a COVID-19 treatment.
On Thursday, the WHO said its trials concluded the drug to have little or no effect on mortality or length of hospital stays, but the American company says the data is inconsistent and its findings premature.
It says other studies have validated the drug’s benefits.
Remdesivir was used to treat US President Donald Trump's COVID-19 infection earlier this month.